↑Diepvens K, Häberer D, Westerterp-Plantenga M (Mar 2008). Different proteins and biopeptides differently affect satiety and anorexigenic/orexigenic hormones in healthy humans. Int J Obes (Lond). 32 (3): 510—8. doi:10.1038/sj.ijo.0803758. PMID18345020.
↑Purnell JQ, Weyer C (2003). Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity. Treatments in Endocrinology. 2 (1): 33—47. doi:10.2165/00024677-200302010-00004. PMID15871553.
↑Hermansen K, Mortensen LS (2007). Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Safety. 30 (12): 1127—42. doi:10.2165/00002018-200730120-00005. PMID18035865.
↑Strasser F, Bruera ED (June 2002). Update on anorexia and cachexia. Hematology/Oncology Clinics of North America. 16 (3): 589—617. doi:10.1016/s0889-8588(02)00011-4. PMID12170570.
↑Morley JE (2007). Weight loss in older persons: new therapeutic approaches. Current Pharmaceutical Design. 13 (35): 3637—47. doi:10.2174/138161207782794149. PMID18220800.
↑Fox CB, Treadway AK, Blaszczyk AT, Sleeper RB (April 2009). Megestrol acetate and mirtazapine for the treatment of unplanned weight loss in the elderly. Pharmacotherapy. 29 (4): 383—97. doi:10.1592/phco.29.4.383. PMID19323618.
↑Holmes S (July 2009). A difficult clinical problem: diagnosis, impact and clinical management of cachexia in palliative care. International Journal of Palliative Nursing. 15 (7): 320, 322—6. doi:10.12968/ijpn.2009.15.7.43421. PMID19648846.